ISG15 induction is required during L1-mediated colon cancer progression and metastasis.

ISG15 L1 colorectal cancer metastasis

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
24 Dec 2019
Historique:
received: 22 10 2019
accepted: 02 12 2019
entrez: 7 1 2020
pubmed: 7 1 2020
medline: 7 1 2020
Statut: epublish

Résumé

Hyperactivation of Wnt/β-catenin target gene expression is a hallmark of colorectal cancer (CRC) development. We identified L1-CAM (L1) and Nr-CAM, members of the immunoglobulin family of nerve cell adhesion receptors, as target genes of the Wnt/β-catenin pathway in CRC cells. L1 overexpression in CRC cells enhances their motile and tumorigenic capacity and promotes liver metastasis. L1 is often localized at the invasive edge of CRC tissue. Using gene arrays and proteomic analyses we identified downstream signaling pathways and targets of L1-mediated signaling. Here, we found that the expression of interferon-stimulated gene 15 (ISG15) that operates much like ubiquitin (is conjugated to proteins by ISGylation), is elevated in the conditioned medium and in CRC cells overexpressing L1. Suppression of endogenous ISG15 levels in L1-expressing cells blocked the increased proliferative, motile, tumorigenic and liver metastatic capacities of CRC cells. ISG15 overexpression, on its own, could enhance these properties in CRC cells, but only to a much lower extent compared to L1. We show that NF-κB signaling is involved in the L1-mediated increase in ISG15, since blocking the NF-κB pathway abolished the induction of ISG15 by L1. Point mutations in the L1 ectodomain that interfere with its binding to L1 ligands, also inhibited the increase in ISG15. We detected high levels of ISG15 in human CRC tissue cells and in the adjacent stroma, but not in the normal mucosa. The results suggest that ISG15 is involved in L1-mediated CRC development and is a potential target for CRC therapy.

Identifiants

pubmed: 31903170
doi: 10.18632/oncotarget.27390
pii: 27390
pmc: PMC6935256
doi:

Types de publication

Journal Article

Langues

eng

Pagination

7122-7131

Informations de copyright

Copyright: © 2019 Cheriyamundath et al.

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST No potential of conflicts of interest were identified.

Références

Oncotarget. 2019 Aug 27;10(50):5217-5228
pubmed: 31497251
Cancer Res. 2013 Sep 15;73(18):5754-63
pubmed: 24008320
Int J Gynecol Pathol. 2014 Jan;33(1):16-22
pubmed: 24300530
Hum Mol Genet. 2000 Apr 12;9(6):879-86
pubmed: 10767310
Genes Dev. 2002 Aug 15;16(16):2058-72
pubmed: 12183361
Biochem Biophys Res Commun. 2005 Oct 21;336(2):496-506
pubmed: 16139798
Oncogene. 2013 Jul 4;32(27):3220-30
pubmed: 22869145
Oncotarget. 2015 Oct 27;6(33):34389-401
pubmed: 26399194
Cancer Lett. 2018 Dec 1;438:52-62
pubmed: 30213559
Oncoimmunology. 2015 Jun 1;4(12):e1052935
pubmed: 26587329
F1000Res. 2018 Sep 18;7:
pubmed: 30271576
J Interferon Cytokine Res. 2008 Sep;28(9):541-51
pubmed: 18715197
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10200-5
pubmed: 16009940
Oncogene. 2016 Feb 4;35(5):549-57
pubmed: 25915847
Oncogene. 2017 Mar;36(11):1597-1606
pubmed: 27641335
Cell. 2000 Oct 13;103(2):311-20
pubmed: 11057903
Trends Neurosci. 1995 Apr;18(4):168-72
pubmed: 7778187
J Cell Sci. 2010 Jun 15;123(Pt 12):2135-43
pubmed: 20501702
Cancer Lett. 2018 Jun 28;424:9-18
pubmed: 29551399
J Cell Biol. 2005 Feb 14;168(4):633-42
pubmed: 15716380
Cytokine Growth Factor Rev. 2012 Dec;23(6):307-14
pubmed: 22906767
J Cell Sci. 2017 Sep 15;130(18):2961-2969
pubmed: 28842471
Cancer Res. 2007 Aug 15;67(16):7703-12
pubmed: 17699774
Neoplasia. 2018 Jul;20(7):697-709
pubmed: 29852322
Oncotarget. 2016 Nov 8;7(45):74393-74409
pubmed: 27626310

Auteurs

Sanith Cheriyamundath (S)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.

Sayon Basu (S)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.

Gal Haase (G)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.

Harry Doernberg (H)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.

Nancy Gavert (N)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.

Thomas Brabletz (T)

Experimental Medicine I, Nikolaus-Fiebiger-Center for Molecular Medicine, University of Erlangen-Nuernberg, Erlangen 91054, Germany.

Avri Ben-Ze'ev (A)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.

Classifications MeSH